Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315039 · ClinicalTrials.gov registry record · Phase 1
Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Moleculin Biotech.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03315039 is a Phase 1 study that has completed, run by Moleculin Biotech. The registered enrollment target is 7 participants.
The verdict
NCT03315039, a Phase 1 study, has completed, sponsored by Moleculin Biotech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy
Interventions
- DRUG Liposomal Annamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-03-28 |
| Est. Completion | 2020-06-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315039
The ClinicalTrials.gov registry entry for NCT03315039 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Moleculin Biotech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liposomal Annamycin is the first listed.
NCT03315039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03315039 about?
NCT03315039 is a clinical study titled "Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)". This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy
What is the current status of trial NCT03315039?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2018-03-28. Estimated completion is 2020-06-20.
What interventions are being tested in trial NCT03315039?
The interventions under investigation include: Liposomal Annamycin (DRUG).
Who is sponsoring clinical trial NCT03315039?
This trial is sponsored by Moleculin Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.